The Morphosis Capital Fund II has launched PRIMIA MEDICAL, a new women's health network built on two companies already active in Romania: the Umana Fertility clinic and the Royal Hospital private hospital. The project is backed by Morphosis Capital, and the network aims to become a major player in the segment of medical services dedicated to women, with growth plans both through acquisitions and through the opening of new units.
The chairman of the board and co-investor of the project is George Peltecu, an entrepreneur in the medical field. The executive leadership of the new network has been entrusted to Dr. Victor Stoian, appointed chief executive officer of PRIMIA MEDICAL. The new structure thus brings together a reproductive medicine component and a surgical and inpatient care component, both oriented toward women's health.
Umana Fertility is a fertility clinic and embryo genetic testing provider, founded in 2023 through a greenfield investment of approximately 3 million euros, meaning it was started from scratch without taking over an existing unit. The clinic has units in Bucharest and Brasov and brings together around 25 specialists. Royal Hospital is a private hospital specialized in gynecology, breast surgery and minimally invasive surgery. The unit has 52 beds, three operating theaters and an intensive care unit with 15 beds, which allows it to manage complex interventions and longer hospital stays.
According to available information, the network's development plan will unfold in stages. The first stage targets the expansion of fertility services and complex surgery, followed by an objective oriented toward prevention and longevity. Growth will be achieved both through acquisitions and through the opening of new units. The timing for announcing new locations and acquisition targets has not been specified, and neither have the financial terms of the transaction been made public.
Among the anchor investors of the project are the European Investment Fund and the InvestEU programme, through Romania's resilience fund-of-funds. The participation of these institutions shows that the network's financing relies on European investment support mechanisms, not only on private capital. The difference between the type of financing and the shareholder structure is to be clarified as the expansion plans take shape.
Morphosis Capital was founded by four entrepreneurs, including Simona Gemeneanu. The fund's portfolio includes the companies Medima Health, EMI, Cronos Med and EnduroSat, which shows an orientation toward several fields, from health to space technology. In 2023, Morphosis exited an investment by selling the Dr. Leahu dental clinics to Regina Maria, an example of a transaction through which the fund recovered its capital from one of its companies.
Several consultants were involved in the transaction establishing the network, including RTPR, Forvis Mazars, EY and Popovici Nitu Stoica & Asociatii, each with a role in structuring and verifying the operation. The PRIMIA MEDICAL network thus enters a market in which services dedicated to women, from fertility to specialized surgery, are becoming increasingly relevant to investors.